Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 23764

Original article / research
Year : 2017 | Month : September | Volume : 11 | Issue : 9 | Page : WC08 - WC11

Clinical Efficacy and Safety on Combining 20% Trichloroacetic Acid Peel with Topical 5% Ascorbic Acid for Melasma

Surabhi Dayal, Priyadarshini Sahu, Manoj Yadav, VK Jain

1. Professor, Department of Dermatology, Pt. B. D. Sharma, PGIMS, Rohtak, Haryana, India. 2 Assistant Professor, Department of Dermatology, Pt. B. D. Sharma, PGIMS, Rohtak, Haryana, India. 3. Consultant, Department of Dermatology, Civil General Hospital, Rewari, Haryana, India. 4. Senior Professor and Head, Department of Dermatology, Pt. B. D. Sharma, PGIMS, Rohtak, Haryana, India.

Correspondence Address :
Dr. Surabhi Dayal,
18, Vikas Nagar, Rohtak-124001, Haryana, India.
E-mail : surabhidayal7@gmail.com

Abstract

Introduction: Trichloroacetic Acid (TCA) is a versatile peeling agent for treatment of melasma. However, Post-Inflammatory Hyperpigmentation (PIH) is reported to be the most common side-effect associated with TCA peel. Topical Ascorbic Acid (AA) due to its effect as antioxidant and tyrosinase inhibitor helps to prevent PIH and maintains the response.

Aim: To assess the clinical efficacy, safety and reduction in Melasma Quality of Life (MELASQOL) on combining 20% TCA peel with 5% ascorbic acid cream in epidermal melasma.

Materials and Methods: This study was conducted in the Department of Dermatology, Pt. Bhagwat Dayal Sharma University of Health Sciences, Rohtak. This was an open labelled prospective randomized study in which 60 patients of epidermal melasma were enrolled for 12 weeks. Patients were divided into two groups: Combination group received 20% TCA peel every two weeks with once daily 5% ascorbic acid cream and Control group received only 20% TCA peel. Melasma Area Severity Index (MASI) was used for evaluating clinical improvement of melasma. Improvement in Quality Of Life (QoL) was assessed by MELASQOL scale in both groups. Adverse effects were evaluated at each visit. All statistical analysis was carried out with SPSS 20th version. The difference in change in mean MASI scoring and MELASQOL scores between the two groups were analysed using Mann-Whitney test. The side effects between the two groups were compared using Chi-square test.

Results: The combination group demonstrated a statistically significant improvement in MASI, percentage decrease in MASI and quality of life as compared to control group after treatment. At the baseline there was no statistically significant difference in MASI between the two groups (i.e., MASI in combination group and control group were 23.55±4.61 and 23.613±4.088 respectively). However, it was statistically significant at the end of therapy (i.e., MASI in combination group was 9.50±5.31 and in control group was 15.10±4.44). When the results were analysed in terms of percentage decrease in MASI from baseline, there was statistically significant difference in combination group (i.e., 10.87±4.11) as compared to control group (i.e., 6.3±1.97) after 2nd week of therapy. When the mean MELASQOL scores were compared between the two groups at the end of therapy (i.e., 12 weeks), it was found to be statistically significantly lower in combination group (16.60±8.03) as compared to control group (25.90±8.17). Minor adverse effects like post peel erythema, pruritus, burning and stinging sensation were observed in some of the patients, which didn’t necessitate termination of the therapy.

Conclusion: Combination of 20% TCA peel with topical 5% ascorbic acid is a highly effective, safe and promising therapeutic option in treatment of melasma which significantly improves the QoL

Keywords

MASI, Peel, Quality of life, Topical vitamin C

How to cite this article :

Surabhi Dayal, Priyadarshini Sahu, Manoj Yadav, VK Jain. CLINICAL EFFICACY AND SAFETY ON COMBINING 20% TRICHLOROACETIC ACID PEEL WITH TOPICAL 5% ASCORBIC ACID FOR MELASMA. Journal of Clinical and Diagnostic Research [serial online] 2017 September [cited: 2018 Jan 22 ]; 11:WC08-WC11. Available from
http://www.jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=September&volume=11&issue=9&page=WC08-WC11&id=10685

DOI and Others

DOI: 10.7860/JCDR/2017/26078.10685

Date of Submission: Dec 16, 2016
Date of Peer Review: Feb 17, 2017
Date of Acceptance: Jun 23, 2017
Date of Publishing: Sep 01, 2017

FINANCIAL OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2016: 132.37
  • SCOPUS
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhost
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com